BAUSCH + LOMB PHARMACEUTICAL RETINA PORTFOLIO
The Bausch + Lomb Pharmaceutical Retina Portfolio is available to help you meet your patients' therapeutic needs. We know you have many choices when it comes to treating your patients.
Personalized patient assistance programs are available from Bausch + Lomb for these treatment options.
INDICATION AND IMPORTANT SAFETY INFORMATION
MACUGEN® (pegaptanib sodium injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration.
MACUGEN® (pegaptanib sodium injection) is contraindicated in patients with ocular or periocular infections, and in patients with known hypersensitivity to pegaptanib sodium or any other excipient in this product.
Click here for additional Important Safety Information for MACUGEN®
RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Surgical placement of RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is contraindicated in active viral, bacterial, mycobacterial or fungal infections of the eye.
Click here for additional Important Safety Information for RETISERT®
VISUDYNE® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
VISUDYNE® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.
Click here for additional Important Safety Information for VISUDYNE®